These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 23072062)
1. Rare diseases mean big profits. Murphy RM Fortune; 2012 Sep; 166(4):24. PubMed ID: 23072062 [No Abstract] [Full Text] [Related]
2. Importance of transparency in assessing the feasibility of modeling rare disease. Johnson SJ; Davis MR; Wang ST Med Decis Making; 2015 Feb; 35(2):143-4. PubMed ID: 25505051 [No Abstract] [Full Text] [Related]
3. The need for transparency and efficiency in reimbursement decisions relating to drugs for rare diseases. Coyle DA; Cheung MC; Evans GA Med Decis Making; 2015 Feb; 35(2):145-7. PubMed ID: 25505026 [No Abstract] [Full Text] [Related]
4. The European rare diseases therapeutic initiative. Fischer A; Borensztein P; Roussel C PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832 [TBL] [Abstract][Full Text] [Related]
5. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives. John JE Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052 [No Abstract] [Full Text] [Related]
10. Small biotechs raring to cash in on the orphan disease market. Hersher R Nat Med; 2012 Mar; 18(3):330-1. PubMed ID: 22395682 [No Abstract] [Full Text] [Related]
11. Eculizumab in paroxysmal nocturnal hemoglobinuria. Pride YB N Engl J Med; 2006 Dec; 355(26):2787; author reply 2787-8. PubMed ID: 17195305 [No Abstract] [Full Text] [Related]
12. [Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria]. Nau JY Rev Med Suisse; 2006 Oct; 2(81):2255. PubMed ID: 17076159 [No Abstract] [Full Text] [Related]
13. Jumpstarting research into neglected diseases. Leslie M Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963 [TBL] [Abstract][Full Text] [Related]
14. Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria. Med Lett Drugs Ther; 2007 Sep; 49(1270):79-80. PubMed ID: 17878890 [No Abstract] [Full Text] [Related]
15. Eculizumab in paroxysmal nocturnal hemoglobinuria. Takita M; Matsumura T; Kami M N Engl J Med; 2006 Dec; 355(26):2787; author reply 2787-8. PubMed ID: 17193722 [No Abstract] [Full Text] [Related]
16. Adverse reactions and medical approach to paroxysmal nocturnal hemoglobinuria. Colombo GM; Guglielmelli E; Sacco T; Cicchinelli M Minerva Med; 2007 Feb; 98(1):87-8. PubMed ID: 17372586 [No Abstract] [Full Text] [Related]
17. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Schrezenmeier H; Höchsmann B Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989 [TBL] [Abstract][Full Text] [Related]
18. Update on eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Hill A Clin Adv Hematol Oncol; 2008 Jul; 6(7):499-500. PubMed ID: 18654116 [No Abstract] [Full Text] [Related]
19. Eculizumab in paroxysmal nocturnal hemoglobinuria. Singh J; Malani AK; Pabla M N Engl J Med; 2006 Dec; 355(26):2786; author reply 2787-8. PubMed ID: 17195307 [No Abstract] [Full Text] [Related]
20. [Progress in the management of paroxysmal nocturnal hemoglobinuria by eculizumab]. Nakakuma H Rinsho Ketsueki; 2011 Aug; 52(8):633-44. PubMed ID: 21897069 [No Abstract] [Full Text] [Related] [Next] [New Search]